The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses the use of BTK degraders for patients with chronic lymphocytic leukemia (CLL) and low-grade lymphomas. Dr El-Sharkawi highlights the mechanism of action of these agents, which halt BTK enzymatic function and degrade the protein. An ongoing Phase I trial (NCT05131022) is evaluating the safety, tolerability, and preliminary efficacy of oral BTK degrader NX-5948 in adult patients with relapsed/refractory (R/R) B-cell malignancies, and results have thus far shown promise, with limited cases of treatment-related adverse events. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie; AstraZeneca; Beigene; Gilead, Janssen; Lily; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis; Roche
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kiirin
